A clinical evaluation of the performance characteristics of one membrane and five bubble oxygenators: haemocompatibility studies

The haemocompatibility of five different bubble oxygenators (Polystan venotherm, Harvey H-1700, Bentley BIO-10, Gambro 10 and Shiley S-100A HED) and one membrane oxygenator (Cobe CML) have been evaluated during standardized clinical perfusion for open-heart surgery in 48 adult patients. Control of arterial PO2 and PCO2 was an important feature of the evaluation protocol. Over the period of cardiopulmonary bypass (CPB) there was a marked difference in the mean percentage reduction in platelet count in the different oxygenator groups. Only 1% reduction in platelet count occurred with the Cobe CML membrane oxygenator group compared with, in the bubble oxygenator groups, 7% for the Gambro 10, 16% for the Harvey H-1700, 19% for the Shiley S-100A HED, 24% for the Bentley BIO-10 and 31% for the Polystan venotherm. The post bypass platelet count was significantly lower than the prebypass value in all oxygenator groups ( p < 0.05) except the Cobe CML and Gambro 10. The two oxygenator groups with the largest percentage reduction in platelet count (Polystan venotherm and Bentley BIO-1 0) demonstrated a significant reduction ( p < 0.05) in platelet aggregation over the period of bypass. Platelet depletion in the Harvey H-1700. Shiley S-100A HED, Bentley BIO-10 and Polystan venotherm oxygenators was associated with a significant fall ( p < 0.05) in mean platelet volume during the first 35 minutes of CPB due to the removal from the circulation of large, young, functionally more active platelets. Erythrocyte damage was minimal in all oxygenator groups and only a minor degree of leucopenia could be demonstrated during the first five minutes of CPB. Cardiotomy suction was not associated with significant changes in platelet numbers or platelet aggregation. When selecting the oxygenator for use in patients undergoing open-heart surgery, gas transfer characteristics and GME production together with the superior preservation of platelet numbers and function in the membrane oxygenator group and variable degree of platelet depletion and reduction in platelet aggregability demonstrated in the five bubble oxygenator groups, must be taken into account.

Does platelet size correlate with function in patients undergoing cardiac surgery?

OBJECTIVE

Platelet dysfunction secondary to cardiopulmonary bypass (CPB) is one of the major reasons for nonsurgical post-operative bleeding in cardiac surgery. Whether platelet size is an indicator for platelet function was investigated in patients undergoing coronary artery bypass grafting.

DESIGN

Prospective study.

SETTING

Intra-operative, cardiac surgery operations.

PATIENTS

80 consecutive patients undergoing coronary artery bypass grafting. Excluding criteria were pre-operative coagulation disorders and medication with anticoagulants within the last 10 days before the operation day.

MEASUREMENTS AND RESULTS

Platelet function was assessed by aggregometry using a turbidimetric method (inductors: ADP 2.0 mumol/l, collagen 4 micrograms/l, epinephrine 25 mumol/l). Mean platelet volume (MPV) was measured by an electrical conductivity method. Measurements were carried out before, during, and after CPB until the 1st post-operative day on intensive care unit (ICU). Platelet size decreased significantly during CPB (max. -25% after weaning from bypass) and returned to baseline values on the 1st post-operative day. Platelet count (ranging from 93 - 304 x 10(9)/l) did not correlate significantly with MPV or aggregation variables. Maximum aggregation and maximum gradient of aggregation induced by ADP and collagen were significantly decreased by CPB with the most pronounced reduction at the end of CPB (ranging from -25% to -45%). Analyses of co-variance revealed a significant correlation between changes in MPV and changes in aggregation variables (ADP, collagen).

CONCLUSIONS

Platelet volume is easy to measure even in the operation room or in ICU and may indicate abnormalities in platelet function in the post-bypass period of cardiac surgery patients.

Does the preparation of heparin influence anticoagulation during cardiopulmonary bypass?

Various preparations of heparin from different manufacturers are commercially available. The influence of bovine lung heparin (BLH) and porcine mucosal heparin (PMH) on anticoagulation and heparin plasma concentration was investigated in four groups of 10 patients undergoing elective aortocoronary bypass grafting either after single dose or repetitive dose (after 60 minutes) of one of these heparin preparations. Heparin plasma concentration increased significantly after injection of heparin (BLH: minimum, 1.67 U/mL; maximum, 2.10 U/mL; PMH: minimum, 1.69 U/mL; maximum, 2.15 U/mL). Sixty minutes after the initial dose, heparin plasma levels were higher in the patients who received PMH. Supplemental heparin doses 60 minutes after the loading dose increased plasma heparin concentration only with porcine mucosal heparin. Elimination of heparin in the urine was not different among the groups. Fibrinogen and antithrombin III concentrations, as well as activated clotting time (ACT; always greater than 400 seconds) and partial thromboplastin time (PTT; always greater than 300 seconds), did not differ among the groups, indicating effective anticoagulation during the bypass period with both types of heparin. It can be concluded that sufficient anticoagulation can be achieved with either kind of heparin. PMH seems to be longer acting and a repeat dose in these patients seems to be necessary only if cardiopulmonary bypass lasts longer than 90 minutes.

Serotonin and acute cardiovascular disorders

In this survey the possible role of serotonin in such acute disorders as systemic and pulmonary hypertension following cardiac surgery is discussed. Although platelets are activated during cardiopulmonary bypass, the increase in serotonin plasma levels is limited because the serotonin released is taken up by normal platelets and endothelial cells. This does not imply that serotonin is not involved in the origin of systemic hypertension during and after cardiac surgery, because subthreshold or threshold doses of this amine amplify the vasoconstrictive effect of, for example, epinephrine and norepinephrine, the levels of which are significantly elevated under these circumstances. That serotonin plays a role through its amplifying effect is supported by the finding that ketanserin, a specific S2-serotonergic receptor antagonist with alpha 1-adrenergic receptor blocking properties, effectively lowers arterial blood pressure in patients with systemic postoperative hypertension by combined blockade of these receptors. The compound is also effective in the treatment of pulmonary hypertension after valve replacement, indicating that serotonin plays a role in the origin of this disorder. This idea is supported by the experimental finding that serotonin induces pulmonary hypertension. It is an interesting observation that, unlike such compounds as nitroprusside, ketanserin does not affect intrapulmonary shunting in patients with systemic hypertension and even reduces the intrapulmonary shunt fraction in patients with pulmonary hypertension. These findings indicate that this compound dilates the resistance vessels in well-ventilated, but not in poorly ventilated areas, and may dilate constricted bronchi.(ABSTRACT TRUNCATED AT 250 WORDS)